$58.20

-0.16 (-0.27%)

7/3/2008 1:00 PM

Biogen Idec, Inc. (BIIB)

CAPS Rating:

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

View Ticker Page (BIIB)

Results 1 - 10 of 66 : 1 2 3 4 5 Next »

Recs

7

Avatar NetscribeBiotech (73.62) Submitted: 2/19/07 2:24 AM : Start Price: $48.00 BIIB Score: -34.47

Biogen Idec Inc, born in 2003 post the merger of Biogen and Idec Pharmaceuticals, develops, manufactures and commercializes novel therapies. With five approved products viz. Avonex, Rituxan, Tysabr, Amevive, Zevalin and several other products in vari...

Report this Post Replies: 4 | Reply | Permalink

Recs

6

Avatar TMFBreakerDave (98.66) Submitted: 6/21/06 12:42 AM : Start Price: $44.94 BIIB Score: 27.67

Long-term biotech play. Biotech has been weak, and BIIB has actually held up pretty well. The return of Tysabri to the market -- albeit in a limited distribution program to start -- is promising, and the stock's rise since November reflects that. Bio...

Report this Post Replies: 2 | Reply | Permalink

Recs

4

Avatar xthecritic (88.20) Submitted: 2/25/08 3:55 PM : Start Price: $59.71 BIIB Score: 3.13

After announcing they are not getting bought the market crushed the stock for the 30% take out premium. However, the company is a solid company with great products. The October guidance for strong growth ahead is still valid. This seems like an easy ...

Report this Post Replies: 0 | Reply | Permalink

Recs

2

Avatar mgknop (< 20) Submitted: 11/22/06 1:04 PM : Start Price: $51.74 BIIB Score: 22.82

Biogen Idec was pummeled after Tysabri was voluntarily pulled; the stock fell approximately 50%. This was a gross over-reaction fueled in part by the Merck Vioxx issues going on. However, Tysabri is used by a group of patients who want desperately to...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar JanessaB (32.18) Submitted: 10/18/06 12:15 PM : Start Price: $43.75 BIIB Score: 37.08

TYSABRI will eventually pick up, as safety data increases. Also, the strategic partnerships are smart, and the company is well-run with a corporate culture that strongly encourages innovation.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar gainloss (36.99) Submitted: 10/06/06 11:24 AM : Start Price: $43.65 BIIB Score: 38.22

Key points:
Tysabri and a management team that always beats expectations--look for the stock to get to $55 easily and $65 long-term, provided Tysabri's introduction goes on as expected.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar TMFBreakerBeth (81.44) Submitted: 5/27/06 3:17 PM : Start Price: $46.27 BIIB Score: 26.95

Looking for good things to happen when Tysabri returns to market.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar Actionman2go (53.62) Submitted: 4/13/07 9:40 AM : Start Price: $45.00 BIIB Score: 42.10

A biopharmaceutical company "engaged primarily in the research, development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases." The company is developing products to treat various autoimm...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar Gouldberg (< 20) Submitted: 9/09/06 5:48 PM : Start Price: $44.10 BIIB Score: 35.93

There's an inherent risk in biotech, but BIIB has the potential for several home runs. Despite some hiccups with latest product Tysabri, their revenue stream is diverse and they should recover nicely. 3rd largest biotech R&D budget ? coupled with BII...

Report this Post Replies: 0 | Reply | Permalink